{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:58:41Z","timestamp":1793843921125,"version":"4.6.1"},"reference-count":403,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,23]]},"abstract":"\n Background:<\/jats:title>\n Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The guideline development process was supported by updated or new systematic evidence reviews. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess evidence and make recommendations.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Recommendations address mechanical and pharmacological prophylaxis in hospitalized medical patients with cancer, those undergoing a surgical procedure, and ambulatory patients receiving cancer chemotherapy. The recommendations also address the use of anticoagulation for the initial, short-term, and long-term treatment of VTE in patients with cancer.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Strong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for initial treatment of VTE in patients with cancer. Conditional recommendations include using thromboprophylaxis in hospitalized medical patients with cancer, LMWH or fondaparinux for surgical patients with cancer, LMWH or direct oral anticoagulants (DOAC) in ambulatory patients with cancer receiving systemic therapy at high risk of VTE and LMWH or DOAC for initial treatment of VTE, DOAC for the short-term treatment of VTE, and LMWH or DOAC for the long-term treatment of VTE in patients with cancer.<\/jats:p>\n <\/jats:sec>","DOI":"10.1182\/bloodadvances.2020003442","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:06:00Z","timestamp":1613145960000},"page":"927-974","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":863,"title":["American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer"],"prefix":"10.1182","volume":"5","author":[{"given":"Gary H.","family":"Lyman","sequence":"first","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[{"name":"Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Leavitt","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and"},{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes Y. Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada;"},{"name":"Division of Medical Oncology, BC Cancer, Vancouver site, Provincial Health Services Authority, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus","family":"Macbeth","sequence":"additional","affiliation":[{"name":"Bristol, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Noble","sequence":"additional","affiliation":[{"name":"Division of Population Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Sexton","sequence":"additional","affiliation":[{"name":"Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-285X","authenticated-orcid":false,"given":"David","family":"Stenehjem","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Minnesota, Duluth, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-1650","authenticated-orcid":false,"given":"Wojtek","family":"Wiercioch","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-0556","authenticated-orcid":false,"given":"Lara A.","family":"Kahale","sequence":"additional","affiliation":[{"name":"American University of Beirut (AUB) Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Center, American University of Beirut, Beirut, Lebanon; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-8504","authenticated-orcid":false,"given":"Pablo","family":"Alonso-Coello","sequence":"additional","affiliation":[{"name":"Cochrane Iberoam\u00e9rica, Biomedical Research Institute Sant Pau\u2013CIBERESP, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"issue":"3","key":"2021032516260235400_B1","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Schunemann","year":"2014","journal-title":"CMAJ"},{"key":"2021032516260235400_B2","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"issue":"7","key":"2021032516260235400_B3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Amir Qaseem","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7","key":"2021032516260235400_B4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2021032516260235400_B5","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2021032516260235400_B6","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2021032516260235400_B7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"2021032516260235400_B8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2021032516260235400_B9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2021032516260235400_B10","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Schunemann","year":"2003","journal-title":"CMAJ"},{"key":"2021032516260235400_B11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2021032516260235400_B12","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","article-title":"Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer","volume":"164","author":"Lyman","year":"2018","journal-title":"Thromb Res"},{"issue":"12","key":"2021032516260235400_B13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"issue":"10","key":"2021032516260235400_B14","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2021032516260235400_B15","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"2021032516260235400_B16","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"2021032516260235400_B17","first-page":"40","article-title":"The incidence of venous thromboembolism in cancer patients: a real-world analysis","volume":"10","author":"Lyman","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"issue":"25","key":"2021032516260235400_B18","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"2021032516260235400_B19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1634\/theoncologist.2015-0361","article-title":"A validated risk score for venous thromboembolism is predictive of cancer progression and mortality","volume":"21","author":"Kuderer","year":"2016","journal-title":"Oncologist"},{"issue":"23","key":"2021032516260235400_B20","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1002\/cncr.24596","article-title":"Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials","volume":"115","author":"Hicks","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"2021032516260235400_B21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cllc.2016.10.007","article-title":"ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism","volume":"18","author":"Zer","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"29","key":"2021032516260235400_B22","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2009.22.4584","article-title":"Impact of venous thromboembolism and anticoagulation on cancer and cancer survival","volume":"27","author":"Kuderer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021032516260235400_B23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2021032516260235400_B24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"2021032516260235400_B25","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"Chee","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2021032516260235400_B26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"2021032516260235400_B27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2009.0006","article-title":"Myeloid growth factors","volume":"7","author":"Crawford","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2021032516260235400_B28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society Of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021032516260235400_B29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00520-017-3854-x","article-title":"A systematic literature review of the efficacy, effectiveness, and safety of filgrastim","volume":"26","author":"Dale","year":"2018","journal-title":"Support Care Cancer"},{"issue":"17","key":"2021032516260235400_B30","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021032516260235400_B31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"2021032516260235400_B32","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"2021032516260235400_B33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2021032516260235400_B34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11739-014-1087-2","article-title":"Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need","volume":"9","author":"Lyman","year":"2014","journal-title":"Intern Emerg Med"},{"issue":"1","key":"2021032516260235400_B35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11239-007-0102-0","article-title":"Cancer and venous thromboembolism: prevention, treatment and survival","volume":"25","author":"Lee","year":"2008","journal-title":"J Thromb Thrombolysis"},{"key":"2021032516260235400_B36","first-page":"453","article-title":"Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study","volume":"8","author":"Seaman","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"2021032516260235400_B37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/PPA.S79373","article-title":"Patients\u2019 experiences of living with cancer-associated thrombosis: the PELICAN study","volume":"9","author":"Noble","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"2021032516260235400_B38","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1007\/s00520-018-4174-5","article-title":"Patients' experience of living with cancer-associated thrombosis in Spain (PELICANOS)","volume":"26","author":"Font","year":"2018","journal-title":"Support Care Cancer"},{"issue":"9","key":"2021032516260235400_B39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2015.0133","article-title":"Cancer-associated venous thromboembolic disease, version 1.2015","volume":"13","author":"Streiff","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"2021032516260235400_B40","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/S0049-3848(16)30115-3","article-title":"The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH\/warfarin\/DOACs?","volume":"140","author":"Noble","year":"2016","journal-title":"Thromb Res"},{"issue":"11","key":"2021032516260235400_B41","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2021032516260235400_B42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0269216318815377","article-title":"Oral anticoagulation is preferable to injected, but only if it is safe and effective: an interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial","volume":"33","author":"Hutchinson","year":"2019","journal-title":"Palliat Med"},{"issue":"5","key":"2021032516260235400_B43","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/1359105314540965","article-title":"Predicting post-traumatic stress and health anxiety following a venous thrombotic embolism","volume":"21","author":"Bennett","year":"2016","journal-title":"J Health Psychol"},{"issue":"4","key":"2021032516260235400_B44","doi-asserted-by":"crossref","first-page":"e004561","DOI":"10.1136\/bmjopen-2013-004561","article-title":"Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study","volume":"4","author":"Noble","year":"2014","journal-title":"BMJ Open"},{"key":"2021032516260235400_B45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2018.05.025","article-title":"Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: a cross-sectional structural equation model","volume":"172","author":"Feehan","year":"2018","journal-title":"Thromb Res"},{"key":"2021032516260235400_B46","doi-asserted-by":"crossref","unstructured":"Wiercioch W, Nieuwlaat R, Akl EA, et al. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Adv. 2020;4(10):2351-2365.","DOI":"10.1182\/bloodadvances.2020001768"},{"key":"2021032516260235400_B47","volume-title":"Conflict of Interest in Medical Research, Education, and Practice","author":"Lo","year":"2009"},{"issue":"11","key":"2021032516260235400_B48","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jclinepi.2014.05.006","article-title":"Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study","volume":"67","author":"Akl","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2021032516260235400_B49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2021032516260235400_B50","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.200901-0126ST","article-title":"An official American Thoracic Society Policy statement: managing conflict of interest in professional societies","volume":"180","author":"Sch\u00fcnemann","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2021032516260235400_B51","first-page":"CD009447","article-title":"Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021032516260235400_B52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"2021032516260235400_B53","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"2021032516260235400_B54","unstructured":"American Society of Hematology. ASH clinical practice guidelines on venous thromboembolism. Available at: https:\/\/hematology.org\/education\/clinicians\/guidelines-and-quality-care\/clinical-practice-guidelines\/venous-thromboembolism-guidelines. Accessed 11 January 2021."},{"issue":"1","key":"2021032516260235400_B55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","article-title":"Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer","volume":"127","author":"Carrier","year":"2014","journal-title":"Am J Med"},{"issue":"4","key":"2021032516260235400_B56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001721-200306000-00004","article-title":"Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study","volume":"14","author":"Alikhan","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"7537","key":"2021032516260235400_B57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"issue":"2","key":"2021032516260235400_B58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1358863X07079017","article-title":"Thromboprophylaxis with dalteparin in medical patients: which patients benefit?","volume":"12","author":"Cohen","year":"2007","journal-title":"Vasc Med"},{"issue":"22","key":"2021032516260235400_B59","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2021032516260235400_B60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11239-015-1294-3","article-title":"Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis","volume":"42","author":"Ageno","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2021032516260235400_B61","first-page":"CD003747","article-title":"Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)","author":"Alikhan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021032516260235400_B62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1331.2006.01536.x","article-title":"Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles","volume":"14","author":"Andr\u00e9","year":"2007","journal-title":"Eur J Neurol"},{"issue":"5","key":"2021032516260235400_B63","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jhm.450","article-title":"How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials","volume":"4","author":"Bump","year":"2009","journal-title":"J Hosp Med"},{"issue":"4","key":"2021032516260235400_B64","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/0003-4819-146-4-200702200-00007","article-title":"Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients","volume":"146","author":"Dentali","year":"2007","journal-title":"Ann Intern Med"},{"key":"2021032516260235400_B65","doi-asserted-by":"crossref","first-page":"C8","DOI":"10.1093\/eurheartj\/sun004","article-title":"Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention","volume":"10","author":"Eikelboom","year":"2008","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"2021032516260235400_B66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.thromres.2006.03.010","article-title":"What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?","volume":"119","author":"Kamphuisen","year":"2007","journal-title":"Thromb Res"},{"issue":"11","key":"2021032516260235400_B67","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.clinthera.2007.11.015","article-title":"Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients","volume":"29","author":"Kanaan","year":"2007","journal-title":"Clin Ther"},{"issue":"9","key":"2021032516260235400_B68","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-155-9-201111010-00008","article-title":"Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline","volume":"155","author":"Lederle","year":"2011","journal-title":"Ann Intern Med"},{"issue":"3","key":"2021032516260235400_B69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1538-7836.2007.02847.x","article-title":"Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis","volume":"6","author":"Lloyd","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2021032516260235400_B70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/cpr.13.55","article-title":"Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux","volume":"10","author":"Loffredo","year":"2013","journal-title":"Clin Pract"},{"issue":"5","key":"2021032516260235400_B71","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1538-7836.2011.04241.x","article-title":"Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies","volume":"9","author":"Paciaroni","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2021032516260235400_B72","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4103\/0972-5229.133902","article-title":"Thrombo-prophylaxis in acutely ill medical and critically ill patients","volume":"18","author":"Saigal","year":"2014","journal-title":"Indian J Crit Care Med"},{"issue":"3","key":"2021032516260235400_B73","first-page":"CD000024","article-title":"Anticoagulants for acute ischaemic stroke","volume":"2015","author":"Sandercock","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021032516260235400_B74","first-page":"CD000119","article-title":"Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke","volume":"4","author":"Sandercock","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021032516260235400_B75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2796.2007.01878.x","article-title":"Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis","volume":"263","author":"Sj\u00e4lander","year":"2008","journal-title":"J Intern Med"},{"issue":"14","key":"2021032516260235400_B76","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archinte.167.14.1476","article-title":"Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials","volume":"167","author":"Wein","year":"2007","journal-title":"Arch Intern Med"},{"issue":"7","key":"2021032516260235400_B77","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00003246-198207000-00006","article-title":"High risk of the critically ill for venous thromboembolism","volume":"10","author":"Cade","year":"1982","journal-title":"Crit Care Med"},{"key":"2021032516260235400_B78","first-page":"31","article-title":"Low molecular weight heparin In acute ischemic stroke","volume":"99","author":"Chaudhry","year":"2002","journal-title":"Antiseptic"},{"issue":"2","key":"2021032516260235400_B79","first-page":"159","article-title":"Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial","volume":"16","author":"Dahan","year":"1986","journal-title":"Haemostasis"},{"issue":"23","key":"2021032516260235400_B80","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/BF01727666","article-title":"Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage","volume":"66","author":"Dickmann","year":"1988","journal-title":"Klin Wochenschr"},{"issue":"1","key":"2021032516260235400_B81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0248-8663(05)80622-8","article-title":"Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients) [in French]","volume":"11","author":"Elias","year":"1990","journal-title":"Rev Med Interne"},{"issue":"9012","key":"2021032516260235400_B82","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(96)91009-0","article-title":"Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases","volume":"347","author":"G\u00e4rdlund","year":"1996","journal-title":"Lancet"},{"issue":"9065","key":"2021032516260235400_B83","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","journal-title":"Lancet"},{"issue":"26","key":"2021032516260235400_B84","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1056\/NEJMoa1111288","article-title":"Low-molecular-weight heparin and mortality in acutely ill medical patients","volume":"365","author":"Kakkar","year":"2011","journal-title":"N Engl J Med"},{"issue":"24","key":"2021032516260235400_B85","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJM199512143332402","article-title":"Low-molecular-weight heparin for the treatment of acute ischemic stroke","volume":"333","author":"Kay","year":"1995","journal-title":"N Engl J Med"},{"key":"2021032516260235400_B86","first-page":"234","article-title":"A randomized trial of fraxiparine in acute ischaemic stroke","volume":"5","author":"Kwiecinski","year":"1995","journal-title":"Cerebrovasc Dis"},{"issue":"7","key":"2021032516260235400_B87","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"Leizorovicz","year":"2004","journal-title":"Circulation"},{"issue":"5-6","key":"2021032516260235400_B88","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00228-005-0944-3","article-title":"Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study","volume":"61","author":"Mah\u00e9","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"8042","key":"2021032516260235400_B89","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(77)90728-0","article-title":"Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke","volume":"2","author":"McCarthy","year":"1977","journal-title":"Lancet"},{"issue":"4","key":"2021032516260235400_B90","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0003-9993(95)80657-1","article-title":"Deep vein thrombosis: prevention in stroke patients during rehabilitation","volume":"76","author":"Pambianco","year":"1995","journal-title":"Arch Phys Med Rehabil"},{"issue":"5","key":"2021032516260235400_B91","first-page":"245","article-title":"Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165\/Fragmin) in stroke patients","volume":"19","author":"Prins","year":"1989","journal-title":"Haemostasis"},{"issue":"11","key":"2021032516260235400_B92","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients","volume":"341","author":"Samama","year":"1999","journal-title":"N Engl J Med"},{"key":"2021032516260235400_B93","first-page":"25","article-title":"A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke","volume":"16","author":"Sandset","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"2021032516260235400_B94","volume-title":"Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution","author":"Duke","year":"1983"},{"key":"2021032516260235400_B95","first-page":"19","article-title":"Fraxiparine in Ischaemic Stroke Study (FISS bis)","volume":"8","author":"Hommel","year":"1998","journal-title":"Cerebrovasc Dis"},{"key":"2021032516260235400_B96","volume-title":"Thromboses Veineuses des Membres Inferieurs et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d\u2019un Essai Comparitif de Traitement Preventif [dissertation]","author":"Pince","year":"1981"},{"key":"2021032516260235400_B97","volume-title":"Trial of tinzaparin versus placebo in ischaemic stroke","author":"Vissinger","year":"1995"},{"issue":"2","key":"2021032516260235400_B98","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"HIDDen: Hospice Inpatient Deep vein thrombosis Detection prospective longitudinal observational study to explore the prevalence, symptom burden and natural history of venous thromboembolism in people with advanced cancer","volume":"6","author":"White","year":"2019","journal-title":"Lancet Haematol"},{"issue":"3","key":"2021032516260235400_B99","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jth.13606","article-title":"Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study","volume":"15","author":"Tardy","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2021032516260235400_B100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ajh.24700","article-title":"Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool","volume":"92","author":"Patell","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"2021032516260235400_B101","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1155\/2002\/310841","article-title":"Economic evaluation of the MEDENOX trial: a Canadian perspective. Medical patients with enoxaparin","volume":"9","author":"Lamy","year":"2002","journal-title":"Can Respir J"},{"issue":"4","key":"2021032516260235400_B102","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1023\/B:PHAR.0000035887.23072.e5","article-title":"Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"26","author":"Offord","year":"2004","journal-title":"Pharm World Sci"},{"issue":"6","key":"2021032516260235400_B103","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1524-4733.2000.36008.x","article-title":"Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients","volume":"3","author":"Pechevis","year":"2000","journal-title":"Value Health"},{"issue":"1","key":"2021032516260235400_B104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/1471-2407-11-316","article-title":"Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY","volume":"11","author":"Haas","year":"2011","journal-title":"BMC Cancer"},{"issue":"3","key":"2021032516260235400_B105","first-page":"127","article-title":"Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients","volume":"26","author":"Harenberg","year":"1996","journal-title":"Haemostasis"},{"issue":"1","key":"2021032516260235400_B106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1078155209104379","article-title":"Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population","volume":"16","author":"Reeves","year":"2010","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"2021032516260235400_B107","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/jth.14139","article-title":"Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer","volume":"16","author":"Parker","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2021032516260235400_B108","first-page":"CD008303","article-title":"Thromboprophylaxis for trauma patients","author":"Barrera","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2021032516260235400_B109","first-page":"CD001922","article-title":"Physical methods for preventing deep vein thrombosis in stroke","author":"Naccarato","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"2021032516260235400_B110","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa1816150","article-title":"Adjunctive intermittent pneumatic compression for venous thromboprophylaxis","volume":"380","author":"Arabi","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2021032516260235400_B111","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1302\/0301-620X.87B8.15680","article-title":"Continuous passive motion in the prevention of deep-vein thrombosis: a randomised comparison in trauma patients","volume":"87","author":"Fuchs","year":"2005","journal-title":"J Bone Joint Surg Br"},{"issue":"2","key":"2021032516260235400_B112","first-page":"127","article-title":"Prophylaxis of deep venous thrombosis after total hip arthroplasty by using intermittent compression of the plantar venous plexus","volume":"25","author":"Stannard","year":"1996","journal-title":"Am J Orthop"},{"key":"2021032516260235400_B113","author":"Yanar"},{"issue":"6","key":"2021032516260235400_B114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/NRL.0b013e3181a93bac","article-title":"Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage","volume":"15","author":"Orken","year":"2009","journal-title":"Neurologist"},{"issue":"16","key":"2021032516260235400_B115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJM198204223061613","article-title":"Prevention of venous thromboembolism in unstable angina pectoris","volume":"306","author":"Salzman","year":"1982","journal-title":"N Engl J Med"},{"issue":"11","key":"2021032516260235400_B116","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/bjs.4309","article-title":"Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma","volume":"90","author":"Ginzburg","year":"2003","journal-title":"Br J Surg"},{"issue":"1","key":"2021032516260235400_B117","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00005373-199201000-00002","article-title":"Thromboembolism following multiple trauma","volume":"32","author":"Knudson","year":"1992","journal-title":"J Trauma"},{"issue":"3","key":"2021032516260235400_B118","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00005373-199409000-00025","article-title":"Prevention of venous thromboembolism in trauma patients","volume":"37","author":"Knudson","year":"1994","journal-title":"J Trauma"},{"issue":"3","key":"2021032516260235400_B119","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00005373-199609000-00010","article-title":"Use of low molecular weight heparin in preventing thromboembolism in trauma patients","volume":"41","author":"Knudson","year":"1996","journal-title":"J Trauma"},{"issue":"8","key":"2021032516260235400_B120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00268-004-7295-6","article-title":"Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin","volume":"28","author":"Kurtoglu","year":"2004","journal-title":"World J Surg"},{"issue":"s2","key":"2021032516260235400_B121","first-page":"692","article-title":"Venous thromboembolism prophylaxis methods in the trauma and emergency surgery intensive care unit patients [abstract]","volume":"7","author":"Kurtoglu","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2021032516260235400_B122","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/j.1538-7836.2012.04874.x","article-title":"Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?","volume":"10","author":"Sharma","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2021032516260235400_B123","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"2021032516260235400_B124","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2021032516260235400_B125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial","volume":"153","author":"Hull","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2021032516260235400_B126","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2021032516260235400_B127","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"Spyropoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2021032516260235400_B128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11060-013-1115-5","article-title":"Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review","volume":"113","author":"Salmaggi","year":"2013","journal-title":"J Neurooncol"},{"issue":"3","key":"2021032516260235400_B129","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ygyno.2007.03.004","article-title":"Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review","volume":"105","author":"Einstein","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2021032516260235400_B130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00268-009-0284-z","article-title":"Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis","volume":"34","author":"Eppsteiner","year":"2010","journal-title":"World J Surg"},{"issue":"2","key":"2021032516260235400_B131","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1245\/s10434-006-9183-9","article-title":"A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality","volume":"14","author":"Leonardi","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2021032516260235400_B132","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00006123-199811000-00039","article-title":"Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors","volume":"43","author":"Dickinson","year":"1998","journal-title":"Neurosurgery"},{"issue":"4","key":"2021032516260235400_B133","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/0002-9378(93)90360-U","article-title":"A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery","volume":"168","author":"Clarke-Pearson","year":"1993","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2021032516260235400_B134","first-page":"989","article-title":"Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial","volume":"98","author":"Maxwell","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2021032516260235400_B135","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1067\/mva.2002.128940","article-title":"External pneumatic compression does not increase urokinase plasminogen activator after abdominal surgery","volume":"36","author":"Murakami","year":"2002","journal-title":"J Vasc Surg"},{"issue":"9","key":"2021032516260235400_B136","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jog.12740","article-title":"Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy","volume":"41","author":"Nagata","year":"2015","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"2021032516260235400_B137","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.thromres.2009.09.009","article-title":"Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study","volume":"125","author":"Sakon","year":"2010","journal-title":"Thromb Res"},{"issue":"3","key":"2021032516260235400_B138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000381034","article-title":"Safety and efficacy of fondaparinux for prophylaxis of venous thromboembolism after colorectal cancer resection: a propensity score matched analysis","volume":"32","author":"Yamaoka","year":"2015","journal-title":"Dig Surg"},{"issue":"6","key":"2021032516260235400_B139","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/j.1875-9114.1996.tb03040.x","article-title":"Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analyses","volume":"16","author":"Mamdani","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2021032516260235400_B140","first-page":"206","article-title":"Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery","volume":"95","author":"Maxwell","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2021032516260235400_B141","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0002-9343(87)90149-5","article-title":"Prevention of venous thromboembolism after general surgery. Cost-effectiveness analysis of alternative approaches to prophylaxis","volume":"82","author":"Oster","year":"1987","journal-title":"Am J Med"},{"issue":"6","key":"2021032516260235400_B142","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/00005373-200012000-00014","article-title":"An evidence-based cost-effectiveness model on methods of prevention of posttraumatic venous thromboembolism","volume":"49","author":"Velmahos","year":"2000","journal-title":"J Trauma"},{"issue":"98","key":"2021032516260235400_B143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19980","article-title":"Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis","volume":"19","author":"Wade","year":"2015","journal-title":"Health Technol Assess"},{"issue":"8","key":"2021032516260235400_B144","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.arth.2012.03.024","article-title":"Cost-effectiveness of venous thromboembolism prophylaxis with a new mobile device after total hip arthroplasty","volume":"27","author":"Cost-effectiveness Writing Committee","year":"2012","journal-title":"J Arthroplasty"},{"issue":"2","key":"2021032516260235400_B145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199807093390204","article-title":"Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery","volume":"339","author":"Agnelli","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"2021032516260235400_B146","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-0038-1650250","article-title":"Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery","volume":"75","author":"Nurmohamed","year":"1996","journal-title":"Thromb Haemost"},{"issue":"13","key":"2021032516260235400_B147","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1245\/s10434-014-3893-1","article-title":"Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial","volume":"21","author":"Song","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2021032516260235400_B148","first-page":"39","article-title":"Prophylactic use of low molecular weight heparin in combination with graduated compression stockings in post-operative patients with gynecologic cancer [in Chinese]","volume":"36","author":"Zheng","year":"2014","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"3","key":"2021032516260235400_B149","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.21037\/jtd.2018.03.13","article-title":"Effect of low molecular weight heparin on venous thromboembolism disease in thoracotomy patients with cancer","volume":"10","author":"Dong","year":"2018","journal-title":"J Thorac Dis"},{"issue":"10","key":"2021032516260235400_B150","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamasurg.2018.2081","article-title":"Venous thromboembolism incidence and prophylaxis use after gastrectomy among Korean patients with gastric adenocarcinoma: the PROTECTOR randomized clinical trial","volume":"153","author":"Jung","year":"2018","journal-title":"JAMA Surg"},{"issue":"5","key":"2021032516260235400_B151","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.21873\/anticanres.13385","article-title":"Efficacy and safety of enoxaparin for prophylaxis of postoperative venous thromboembolism after esophagectomy: a single-center prospective randomized controlled phase II study","volume":"39","author":"Tanaka","year":"2019","journal-title":"Anticancer Res"},{"issue":"2","key":"2021032516260235400_B152","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2004.02.004","article-title":"Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery","volume":"93","author":"Dainty","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2021032516260235400_B153","doi-asserted-by":"crossref","first-page":"20371","DOI":"10.18632\/oncotarget.13620","article-title":"Efficacy of intermittent pneumatic compression for venous thromboembolism prophylaxis in patients undergoing gynecologic surgery: A systematic review and meta-analysis","volume":"8","author":"Feng","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"2021032516260235400_B154","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/CIRCULATIONAHA.113.002690","article-title":"Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients","volume":"128","author":"Ho","year":"2013","journal-title":"Circulation"},{"key":"2021032516260235400_B155","first-page":"CD005258","article-title":"Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism","volume":"9","author":"Kakkos","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2021032516260235400_B156","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/SLA.0000000000001530","article-title":"The use of intermittent pneumatic compression in orthopedic and neurosurgical postoperative patients: a systematic review and meta-analysis","volume":"263","author":"O\u2019Connell","year":"2016","journal-title":"Ann Surg"},{"issue":"2","key":"2021032516260235400_B157","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.arth.2015.09.043","article-title":"Effectiveness of intermittent pneumatic compression devices for venous thromboembolism prophylaxis in high-risk surgical patients: a systematic review","volume":"31","author":"Pavon","year":"2016","journal-title":"J Arthroplasty"},{"issue":"12","key":"2021032516260235400_B158","first-page":"CD001484","article-title":"Graduated compression stockings for prevention of deep vein thrombosis","author":"Sachdeva","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2021032516260235400_B159","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/phar.1206","article-title":"Comparative effectiveness of combined pharmacologic and mechanical thromboprophylaxis versus either method alone in major orthopedic surgery: a systematic review and meta-analysis","volume":"33","author":"Sobieraj","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"9","key":"2021032516260235400_B160","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/bjs.9527","article-title":"Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery","volume":"101","author":"Zareba","year":"2014","journal-title":"Br J Surg"},{"issue":"1","key":"2021032516260235400_B161","first-page":"44","article-title":"Thromboembolic prophylaxis after major abdominal surgery [in Turkish]","volume":"7","author":"Celebi","year":"2001","journal-title":"Ulus Travma Derg"},{"issue":"7","key":"2021032516260235400_B162","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1302\/0301-620X.89B7.18556","article-title":"The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study","volume":"89","author":"Cohen","year":"2007","journal-title":"J Bone Joint Surg Br"},{"issue":"8","key":"2021032516260235400_B163","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.arth.2007.11.006","article-title":"Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty","volume":"23","author":"Edwards","year":"2008","journal-title":"J Arthroplasty"},{"issue":"5","key":"2021032516260235400_B164","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2106\/00004623-200705000-00018","article-title":"Rapid-inflation intermittent pneumatic compression for prevention of deep venous thrombosis","volume":"89","author":"Eisele","year":"2007","journal-title":"J Bone Joint Surg Am"},{"issue":"9","key":"2021032516260235400_B165","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00113-006-1140-3","article-title":"Intermittent compression devices for swelling reduction and thrombosis prophylaxis\u2013a pilot study after total hip replacement. Is the 2 hour daily minimum application sufficient? [in German]","volume":"109","author":"Ivanic","year":"2006","journal-title":"Unfallchirurg"},{"issue":"2","key":"2021032516260235400_B166","first-page":"162","article-title":"Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial","volume":"15","author":"Kalodiki","year":"1996","journal-title":"Int Angiol"},{"issue":"3","key":"2021032516260235400_B167","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2106\/00004623-199403000-00004","article-title":"The prevalence of deep venous thrombosis after total hip arthroplasty with hypotensive epidural anesthesia","volume":"76","author":"Lieberman","year":"1994","journal-title":"J Bone Joint Surg Am"},{"key":"2021032516260235400_B168","unstructured":"Patel A , CoubandD, F\u00e9ronJM, SignoretF. Prevention of deep venous thrombosis in arthroplastic surgery of the hip by the combination of heparinotherapy and the antithrombosis stocking [in French]. Presse Med. 1988;17(23):1201-1203."},{"issue":"1","key":"2021032516260235400_B169","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1378\/chest.109.1.82","article-title":"The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery","volume":"109","author":"Ramos","year":"1996","journal-title":"Chest"},{"issue":"3-4","key":"2021032516260235400_B170","first-page":"193","article-title":"Venous thrombosis after abdominal surgery. A comparison between subcutaneous heparin and antithrombotic stockings, or both","volume":"19","author":"Rasmussen","year":"1988","journal-title":"J Med"},{"issue":"1","key":"2021032516260235400_B171","doi-asserted-by":"crossref","first-page":"e2247","DOI":"10.1097\/MD.0000000000002247","article-title":"Effects of a foot pump on the incidence of deep vein thrombosis after total knee arthroplasty in patients given edoxaban: a randomized controlled study","volume":"95","author":"Sakai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2021032516260235400_B172","first-page":"186","article-title":"Intermittent pneumatic leg compression (IPLC) and unfractionated heparin (UFH) in the prevention of post-operative deep vein thrombosis in hip surgery: a randomized clinical trial","volume":"87","author":"Siragusa","year":"1994","journal-title":"Br J Haematol"},{"issue":"6","key":"2021032516260235400_B173","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2106\/00004623-199606000-00004","article-title":"Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone","volume":"78","author":"Westrich","year":"1996","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"2021032516260235400_B174","first-page":"44","article-title":"Prophylaxis of deep venous thrombosis after acute abdominal operation","volume":"172","author":"Wille-J\u00f8rgensen","year":"1991","journal-title":"Surg Gynecol Obstet"},{"issue":"7","key":"2021032516260235400_B175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/bjs.1800720726","article-title":"Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: a randomized trial","volume":"72","author":"Wille-J\u00f8rgensen","year":"1985","journal-title":"Br J Surg"},{"issue":"7","key":"2021032516260235400_B176","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00264-010-1091-8","article-title":"Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty","volume":"35","author":"Windisch","year":"2011","journal-title":"Int Orthop"},{"issue":"2","key":"2021032516260235400_B177","first-page":"127","article-title":"Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study","volume":"22","author":"Baykal","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"issue":"8","key":"2021032516260235400_B178","first-page":"1099","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment","volume":"84","author":"Bergqvist","year":"1997","journal-title":"Br J Surg"},{"key":"2021032516260235400_B179","first-page":"19","article-title":"Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin","author":"Bergqvist","year":"1990","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"2021032516260235400_B180","first-page":"693","article-title":"Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin","volume":"67","author":"Boncinelli","year":"2001","journal-title":"Minerva Anestesiol"},{"key":"2021032516260235400_B181","article-title":"Prevention of deep venous thromboses in cancer thoracic surgery with a low-molecular-weight heparin. Fraxiparine: a comparative randomized trial","volume-title":"Fraxiparine: Second International Symposium: Recent Pharmacological and Clinical Data.","author":"Dahan","year":"1990"},{"issue":"11","key":"2021032516260235400_B182","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/bjs.1800751105","article-title":"Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery","volume":"75","author":"Encke","year":"1988","journal-title":"Br J Surg"},{"issue":"6","key":"2021032516260235400_B183","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2362.1988.tb01268.x","article-title":"Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery","volume":"18","author":"Fricker","year":"1988","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2021032516260235400_B184","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0038-1657514","article-title":"Prevention of post-operative deep leg vein thrombosis in patients with cancer","volume":"78","author":"Gallus","year":"1997","journal-title":"Thromb Haemost"},{"key":"2021032516260235400_B185","first-page":"647","article-title":"Comparison of the efficacy and safety of subcutaneous RD heparin vs subcutaneous unfractionated heparin for the prevention of deep-vein thrombosis in patients undergoing abdominal or pelvic-surgery for cancer","volume-title":"Thromb Haemost","author":"Godwin","year":"1993"},{"issue":"1","key":"2021032516260235400_B186","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s002689900185","article-title":"Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial","volume":"21","author":"Kakkar","year":"1997","journal-title":"World J Surg"},{"key":"2021032516260235400_B187","first-page":"593","article-title":"A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis","volume":"152","author":"Onarheim","year":"1986","journal-title":"Acta Chir Scand"},{"issue":"3","key":"2021032516260235400_B188","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0038-1655988","article-title":"Blood coagulation and thrombosis in patients with ovarian malignancy","volume":"77","author":"von Tempelhoff","year":"1997","journal-title":"Thromb Haemost"},{"issue":"4","key":"2021032516260235400_B189","first-page":"815","article-title":"Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial","volume":"16","author":"von Tempelhoff","year":"2000","journal-title":"Int J Oncol"},{"issue":"6","key":"2021032516260235400_B190","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1378\/chest.122.6.1933","article-title":"Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis","volume":"122","author":"Goldhaber","year":"2002","journal-title":"Chest"},{"issue":"6","key":"2021032516260235400_B191","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1055\/s-0038-1648513","article-title":"Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery","volume":"67","author":"Koppenhagen","year":"1992","journal-title":"Thromb Haemost"},{"issue":"1","key":"2021032516260235400_B192","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1479-828X.1998.tb02968.x","article-title":"Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery","volume":"38","author":"Ward","year":"1998","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"2021032516260235400_B193","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0038-1649627","article-title":"Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators\u2019 Group","volume":"70","author":"Gallus","year":"1993","journal-title":"Thromb Haemost"},{"issue":"7","key":"2021032516260235400_B194","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2146\/ajhp120711","article-title":"Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery","volume":"71","author":"Changolkar","year":"2014","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"2021032516260235400_B195","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"Br J Surg"},{"issue":"11","key":"2021032516260235400_B196","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/iju.13189","article-title":"Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: a prospective randomized clinical trial","volume":"23","author":"Hata","year":"2016","journal-title":"Int J Urol"},{"key":"2021032516260235400_B197","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2018.04.001","article-title":"Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: a randomized controlled trial","volume":"166","author":"Song","year":"2018","journal-title":"Thromb Res"},{"issue":"6","key":"2021032516260235400_B198","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/SLA.0000000000000430","article-title":"Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial","volume":"259","author":"Kakkar","year":"2014","journal-title":"Ann Surg"},{"issue":"13","key":"2021032516260235400_B199","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"2021032516260235400_B200","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1538-7836.2006.02153.x","article-title":"Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study","volume":"4","author":"Rasmussen","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2021032516260235400_B201","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/SLA.0000000000000340","article-title":"A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer","volume":"259","author":"Vedovati","year":"2014","journal-title":"Ann Surg"},{"issue":"8","key":"2021032516260235400_B202","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/MBC.0b013e328349f1a8","article-title":"The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial","volume":"22","author":"Auer","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"2021032516260235400_B203","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1538-7836.2010.03892.x","article-title":"Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study","volume":"8","author":"Kakkar","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2021032516260235400_B204","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jtcvs.2007.10.036","article-title":"Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer","volume":"135","author":"Dentali","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"2021032516260235400_B205","first-page":"1176","article-title":"Extended perioperative thromboprophylaxis in patients with cancer. A systematic review","volume":"100","author":"Akl","year":"2008","journal-title":"Thromb Haemost"},{"issue":"5","key":"2021032516260235400_B206","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1245\/s10434-016-5127-1","article-title":"Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis","volume":"23","author":"Fagarasanu","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2021032516260235400_B207","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/SLA.0000000000002074","article-title":"Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis","volume":"265","author":"Guo","year":"2017","journal-title":"Ann Surg"},{"issue":"1","key":"2021032516260235400_B208","first-page":"CD004318","article-title":"Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery","author":"Rasmussen","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2021032516260235400_B209","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/110241598750005534","article-title":"Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis","volume":"164","author":"Lausen","year":"1998","journal-title":"Eur J Surg"},{"issue":"4","key":"2021032516260235400_B210","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.juro.2013.10.096","article-title":"Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis","volume":"191","author":"VanDlac","year":"2014","journal-title":"J Urol"},{"key":"2021032516260235400_B211","article-title":"Parenteral anticoagulation in ambulatory patients with cancer","author":"Akl","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2021032516260235400_B212","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3109\/0284186X.2014.934397","article-title":"Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis","volume":"53","author":"Ben-Aharon","year":"2014","journal-title":"Acta Oncol"},{"issue":"5","key":"2021032516260235400_B213","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejim.2013.01.006","article-title":"The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis","volume":"24","author":"Che","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"12","key":"2021032516260235400_B214","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2021032516260235400_B215"},{"issue":"5","key":"2021032516260235400_B216","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/cncr.22892","article-title":"A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications","volume":"110","author":"Kuderer","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"2021032516260235400_B217","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11239-013-1014-9","article-title":"Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis","volume":"38","author":"Phan","year":"2014","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2021032516260235400_B218","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"Sanford","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2021032516260235400_B219","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MBC.0000000000000413","article-title":"Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Tun","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2021032516260235400_B220","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/thoraxjnl-2012-202592","article-title":"Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis","volume":"68","author":"Zhang","year":"2013","journal-title":"Thorax"},{"issue":"3","key":"2021032516260235400_B221","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/ajco.12770","article-title":"Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials (RCTs)","volume":"14","author":"Thein","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"2021032516260235400_B222","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.4103\/0973-1482.176174","article-title":"Low molecular weight heparin in treating patients with lung cancer received chemotherapy: a meta-analysis","volume":"14","author":"Liu","year":"2018","journal-title":"J Cancer Res Ther"},{"issue":"10","key":"2021032516260235400_B223","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"2021032516260235400_B224","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2021032516260235400_B225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10","key":"2021032516260235400_B226","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)","volume":"22","author":"Kakkar","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021032516260235400_B227","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb Res"},{"issue":"10","key":"2021032516260235400_B228","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","article-title":"The effect of low molecular weight heparin on survival in patients with advanced malignancy","volume":"23","author":"Klerk","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021032516260235400_B229","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E","article-title":"Subcutaneous heparin treatment increases survival in small cell lung cancer. \u201cPetites Cellules\u201d Group","volume":"74","author":"Lebeau","year":"1994","journal-title":"Cancer"},{"issue":"6","key":"2021032516260235400_B230","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2013.09.026","article-title":"Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study","volume":"132","author":"Lecumberri","year":"2013","journal-title":"Thromb Res"},{"issue":"5","key":"2021032516260235400_B231","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021032516260235400_B232","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"Perry","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2021032516260235400_B233","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4065\/81.6.758","article-title":"Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial","volume":"81","author":"Sideras","year":"2006","journal-title":"Mayo Clinic Proc"},{"issue":"15","key":"2021032516260235400_B234","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021032516260235400_B235","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00520-007-0339-3","article-title":"Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study","volume":"16","author":"Weber","year":"2008","journal-title":"Support Care Cancer"},{"issue":"4","key":"2021032516260235400_B236","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.12163","article-title":"Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)","volume":"160","author":"Zwicker","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2021032516260235400_B237","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"issue":"18","key":"2021032516260235400_B238","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021032516260235400_B239"},{"key":"2021032516260235400_B240","first-page":"364","article-title":"Randomized study of low molecular weight heparin (LMWH) plus chemotherapy in advanced non-small cell lung cancer","volume":"13","author":"Gu","year":"2003","journal-title":"China Oncol."},{"key":"2021032516260235400_B241"},{"key":"2021032516260235400_B242"},{"key":"2021032516260235400_B243"},{"issue":"24","key":"2021032516260235400_B244","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"2021032516260235400_B245"},{"issue":"7","key":"2021032516260235400_B246","first-page":"CD006466","article-title":"Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation","author":"Akl","year":"2014"},{"issue":"12","key":"2021032516260235400_B247","first-page":"CD006466","article-title":"Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation","volume":"12","author":"Kahale","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2021032516260235400_B248","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1200\/JCO.1989.7.8.993","article-title":"A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B","volume":"7","author":"Chahinian","year":"1989","journal-title":"J Clin Oncol"},{"issue":"8902","key":"2021032516260235400_B249","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"issue":"11","key":"2021032516260235400_B250","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1200\/JCO.1997.15.11.3378","article-title":"Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study","volume":"15","author":"Maurer","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021032516260235400_B251","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/thx.34.1.113","article-title":"Anticoagulants in the treatment of small cell carcinoma of the bronchus","volume":"34","author":"Stanford","year":"1979","journal-title":"Thorax"},{"issue":"10","key":"2021032516260235400_B252","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F","article-title":"Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75","volume":"53","author":"Zacharski","year":"1984","journal-title":"Cancer"},{"issue":"7","key":"2021032516260235400_B253","first-page":"S122","article-title":"The effect of warfarin on survival in patients with lung cancer","volume":"7","author":"Ciftci","year":"2012","journal-title":"J Thor Oncol"},{"issue":"10","key":"2021032516260235400_B254","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM199709043371001","article-title":"Low-molecular-weight heparin in the treatment of patients with venous thromboembolism","volume":"337","author":"Columbus Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"2021032516260235400_B255","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, eds. GRADE Handbook. Introduction to GRADE Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Available at: gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html. Accessed 13 January 2021."},{"issue":"12","key":"2021032516260235400_B256","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/jth.14613","article-title":"Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis","volume":"17","author":"Li","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2021032516260235400_B257","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"2021032516260235400_B258"},{"issue":"5","key":"2021032516260235400_B259","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2021032516260235400_B260"},{"key":"2021032516260235400_B261","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - a systematic review","volume":"141","author":"Al-Ani","year":"2016","journal-title":"Thromb Res"},{"issue":"8","key":"2021032516260235400_B262","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021032516260235400_B263","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2021032516260235400_B264","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.23479","article-title":"Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis","volume":"112","author":"Akl","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"2021032516260235400_B265","first-page":"CD006468","article-title":"Anticoagulation for people with cancer and central venous catheters","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021032516260235400_B266","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1345\/aph.1G714","article-title":"Systemic anticoagulant prophylaxis for central catheter-associated venous thrombosis in cancer patients","volume":"41","author":"Chan","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2021032516260235400_B267","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1160\/TH07-07-0446","article-title":"Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis","volume":"99","author":"Chaukiyal","year":"2008","journal-title":"Thromb Haemost"},{"issue":"6","key":"2021032516260235400_B268","first-page":"CD006468","article-title":"Anticoagulation for people with cancer and central venous catheters","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"2021032516260235400_B269","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1001\/archinte.163.16.1913","article-title":"Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review","volume":"163","author":"Klerk","year":"2003","journal-title":"Arch Intern Med"},{"issue":"12","key":"2021032516260235400_B270","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/annonc\/mdp235","article-title":"Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies","volume":"20","author":"De Cicco","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"2021032516260235400_B271","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/annonc\/mdj059","article-title":"Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial","volume":"17","author":"Karthaus","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"2021032516260235400_B272","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00280-013-2169-y","article-title":"Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study","volume":"72","author":"Lavau-Denes","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2021032516260235400_B273","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1650254","article-title":"Upper extremity deep venous thrombosis in cancer patients with venous access devices\u2013prophylaxis with a low molecular weight heparin (Fragmin)","volume":"75","author":"Monreal","year":"1996","journal-title":"Thromb Haemost"},{"issue":"9","key":"2021032516260235400_B274","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/j.1538-7836.2007.02660.x","article-title":"Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study","volume":"5","author":"Niers","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"18","key":"2021032516260235400_B275","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1200\/JCO.2005.06.084","article-title":"Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients","volume":"23","author":"Verso","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021032516260235400_B276","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1477-7819-8-91","article-title":"Ultrasound-guided central venous catheterization in cancer patients improves the success rate of cannulation and reduces mechanical complications: a prospective observational study of 1,978 consecutive catheterizations","volume":"8","author":"Cavanna","year":"2010","journal-title":"World J Surg Oncol"},{"issue":"9663","key":"2021032516260235400_B277","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(09)60205-1","article-title":"Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial","volume":"373","author":"Young","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"2021032516260235400_B278","first-page":"CD001100","article-title":"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism","author":"Erkens","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021032516260235400_B279","first-page":"CD006649","article-title":"Anticoagulation for the initial treatment of venous thromboembolism in people with cancer","volume":"1","author":"Hakoum","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2021032516260235400_B280","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis","volume":"344","author":"Breddin","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"2021032516260235400_B281","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1647660","article-title":"A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study","volume":"65","year":"1991","journal-title":"Thromb Haemost"},{"issue":"15","key":"2021032516260235400_B282","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM199204093261502","article-title":"Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis","volume":"326","author":"Hull","year":"1992","journal-title":"N Engl J Med"},{"issue":"11","key":"2021032516260235400_B283","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home","volume":"334","author":"Koopman","year":"1996","journal-title":"N Engl J Med"},{"issue":"11","key":"2021032516260235400_B284","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis","volume":"334","author":"Levine","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"2021032516260235400_B285","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0038-1648836","article-title":"Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis","volume":"72","author":"Lindmarker","year":"1994","journal-title":"Thromb Haemost"},{"issue":"1","key":"2021032516260235400_B286","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0038-1656309","article-title":"Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial","volume":"68","author":"Lopaciuk","year":"1992","journal-title":"Thromb Haemost"},{"issue":"3","key":"2021032516260235400_B287","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","article-title":"Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease","volume":"134","author":"Merli","year":"2001","journal-title":"Ann Intern Med"},{"issue":"10","key":"2021032516260235400_B288","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.164.10.1077","article-title":"Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism","volume":"164","author":"Prandoni","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8791","key":"2021032516260235400_B289","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","article-title":"Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis","volume":"339","author":"Prandoni","year":"1992","journal-title":"Lancet"},{"issue":"13","key":"2021032516260235400_B290","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archinte.1993.00410130045005","article-title":"Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis","volume":"153","author":"Simonneau","year":"1993","journal-title":"Arch Intern Med"},{"issue":"10","key":"2021032516260235400_B291","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199709043371002","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l\u2019Embolie Pulmonaire","volume":"337","author":"Simonneau","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"2021032516260235400_B292","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/archinte.165.7.733","article-title":"A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism","volume":"165","author":"Wells","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"2021032516260235400_B293","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1055\/s-0038-1650643","article-title":"Risk factors for bleeding during treatment of acute venous thromboembolism","volume":"76","author":"Wester","year":"1996","journal-title":"Thromb Haemost"},{"issue":"2","key":"2021032516260235400_B294","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.160.2.181","article-title":"A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency","volume":"160","author":"Dolovich","year":"2000","journal-title":"Arch Intern Med"},{"key":"2021032516260235400_B295","first-page":"CD007557","article-title":"Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients","volume":"4","author":"Junqueira","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021032516260235400_B296","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH08-09-0563","article-title":"Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials","volume":"101","author":"van Doormaal","year":"2009","journal-title":"Thromb Haemost"},{"issue":"18","key":"2021032516260235400_B297","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"2021032516260235400_B298","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"B\u00fcller","year":"2004","journal-title":"Ann Intern Med"},{"issue":"6","key":"2021032516260235400_B299","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2021032516260235400_B300","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021032516260235400_B301","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2021032516260235400_B302","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"2021032516260235400_B303","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021032516260235400_B304","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2021032516260235400_B305","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb Res"},{"issue":"1","key":"2021032516260235400_B306","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1078155217727140","article-title":"Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: a systematic literature review of efficacy and cost-effectiveness","volume":"25","author":"Dranitsaris","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"2021032516260235400_B307","first-page":"CD00650.pub5","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2021032516260235400_B308","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.thromres.2012.08.290","article-title":"Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients","volume":"130","author":"Laporte","year":"2012","journal-title":"Thromb Res"},{"issue":"6","key":"2021032516260235400_B309","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(08)70149-9","article-title":"Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis","volume":"9","author":"Noble","year":"2008","journal-title":"Lancet Oncol"},{"issue":"3","key":"2021032516260235400_B310","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"issue":"5","key":"2021032516260235400_B311","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.avsg.2009.08.006","article-title":"Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism","volume":"24","author":"Romera-Villegas","year":"2010","journal-title":"Ann Vasc Surg"},{"issue":"9 suppl","key":"2021032516260235400_B312","doi-asserted-by":"crossref","first-page":"182S","DOI":"10.1177\/1076029618800792","article-title":"Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials","volume":"24","author":"Sobieraj","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"2021032516260235400_B313","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.thromres.2018.08.023","article-title":"Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis","volume":"170","author":"Vedovati","year":"2018","journal-title":"Thromb Res"},{"issue":"4","key":"2021032516260235400_B314","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"2021032516260235400_B315","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"issue":"7","key":"2021032516260235400_B316","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"2021032516260235400_B317","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"2021032516260235400_B318","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"3","key":"2021032516260235400_B319","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis","volume":"37","author":"Romera","year":"2009","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"2021032516260235400_B320","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1160\/TH04-11-0767","article-title":"Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism","volume":"93","author":"Aujesky","year":"2005","journal-title":"Thromb Haemost"},{"issue":"6","key":"2021032516260235400_B321","first-page":"580","article-title":"The efficacy and safety of new oral anticoagulants for cancer-associated venous thromboembolism: a meta-analysis","volume":"18","author":"Chen","year":"2018","journal-title":"Chin J Evid Based Med."},{"issue":"3","key":"2021032516260235400_B322","doi-asserted-by":"crossref","first-page":"1701097","DOI":"10.1183\/13993003.01097-2017","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials","volume":"50","author":"Di Minno","year":"2017","journal-title":"Eur Respir J"},{"issue":"12","key":"2021032516260235400_B323","doi-asserted-by":"crossref","first-page":"e114445","DOI":"10.1371\/journal.pone.0114445","article-title":"Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes","volume":"9","author":"Larsen","year":"2014","journal-title":"PLoS One"},{"key":"2021032516260235400_B324","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"issue":"6","key":"2021032516260235400_B325","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MJT.0000000000000055","article-title":"New oral anticoagulants in patients with cancer: current state of evidence","volume":"22","author":"Sardar","year":"2015","journal-title":"Am J Ther"},{"issue":"7","key":"2021032516260235400_B326","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.12605","article-title":"Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2021032516260235400_B327","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"issue":"12","key":"2021032516260235400_B328","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial","volume":"13","author":"Agnelli","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2021032516260235400_B329","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol"},{"issue":"8","key":"2021032516260235400_B330","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"issue":"22","key":"2021032516260235400_B331","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2021032516260235400_B332","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11239-018-1696-0","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis","volume":"46","author":"Al Yami","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2021032516260235400_B333","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2021032516260235400_B334","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"2021032516260235400_B335","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jth.13172","article-title":"Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients","volume":"14","author":"van der Hulle","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2021032516260235400_B336","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1183\/13993003.00779-2016","article-title":"Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism","volume":"48","author":"Peris","year":"2016","journal-title":"Eur Respir J"},{"key":"2021032516260235400_B337","first-page":"P4108","article-title":"Incidence and management of isolated subsegmental pulmonary embolism","volume":"42","author":"Ates","year":"2013","journal-title":"Eur. Respir. J"},{"issue":"4","key":"2021032516260235400_B338","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/j.thromres.2010.07.001","article-title":"Clinical outcomes in patients with isolated subsegmental pulmonary emboli diagnosed by multidetector CT pulmonary angiography","volume":"126","author":"Donato","year":"2010","journal-title":"Thromb Res"},{"issue":"2","key":"2021032516260235400_B339","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2214\/ajr.184.2.01840623","article-title":"Clinicians\u2019 response to radiologists\u2019 reports of isolated subsegmental pulmonary embolism or inconclusive interpretation of pulmonary embolism using MDCT","volume":"184","author":"Eyer","year":"2005","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"2021032516260235400_B340","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jth.12803","article-title":"Sub-segmental pulmonary embolism in three academic teaching hospitals: a review of management and outcomes","volume":"13","author":"Goy","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2021032516260235400_B341","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2796.1991.tb00453.x","article-title":"The significance of venography in the management of patients with clinically suspected pulmonary embolism","volume":"230","author":"Kruit","year":"1991","journal-title":"J Intern Med"},{"issue":"4","key":"2021032516260235400_B342","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1538-7836.2006.01819.x","article-title":"Diagnosis and management of subsegmental pulmonary embolism","volume":"4","author":"Le Gal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2021032516260235400_B343","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/imj.12507","article-title":"Management and outcomes of single subsegmental pulmonary embolus: a retrospective audit at North Shore Hospital, New Zealand","volume":"44","author":"Mehta","year":"2014","journal-title":"Intern Med J"},{"issue":"4","key":"2021032516260235400_B344","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1378\/chest.107.4.931","article-title":"Untreated patients with pulmonary embolism. Outcome, clinical, and laboratory assessment","volume":"107","author":"Stein","year":"1995","journal-title":"Chest"},{"issue":"9","key":"2021032516260235400_B345","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Ann Intern Med"},{"issue":"12","key":"2021032516260235400_B346","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJMclde1907665","article-title":"Anticoagulation for subsegmental pulmonary embolism","volume":"381","author":"Fernandes","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2021032516260235400_B347","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry","volume":"175","author":"Ageno","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2021032516260235400_B348","first-page":"371","article-title":"Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer","volume":"106","author":"Menapace","year":"2011","journal-title":"Thromb Haemost"},{"issue":"15 suppl","key":"2021032516260235400_B349","doi-asserted-by":"crossref","first-page":"e20658","DOI":"10.1200\/jco.2015.33.15_suppl.e20658","article-title":"Splanchnic vein thrombosis in ambulatory pancreatic cancer patients receiving chemotherapy","volume":"33","author":"Pach\u00f3n Olmos","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021032516260235400_B350","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S2352-3026(16)30020-5","article-title":"Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry","volume":"3","author":"Riva","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"2021032516260235400_B351","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.thromres.2012.07.006","article-title":"Unsuspected visceral venous thrombosis, in patients with cancer of the gastrointestinal system","volume":"130","author":"Bozas","year":"2012","journal-title":"Thromb Res"},{"key":"2021032516260235400_B352"},{"issue":"8","key":"2021032516260235400_B353","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1538-7836.2007.02613.x","article-title":"A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)","volume":"5","author":"Kovacs","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2021032516260235400_B354","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2021032516260235400_B355","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"2021032516260235400_B356","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2021032516260235400_B357","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2021032516260235400_B358","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1378\/chest.127.1.53","article-title":"Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study","volume":"127","author":"Hering","year":"2005","journal-title":"Chest"},{"issue":"5","key":"2021032516260235400_B359","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1055\/s-0038-1656064","article-title":"A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses","volume":"77","author":"Pengo","year":"1997","journal-title":"Thromb Haemost"},{"key":"2021032516260235400_B360","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"issue":"4","key":"2021032516260235400_B361","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2021032516260235400_B362","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.clinthera.2014.06.033","article-title":"Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach","volume":"36","author":"Rollins","year":"2014","journal-title":"Clin Ther"},{"issue":"5","key":"2021032516260235400_B363","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1074248415575154","article-title":"Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review","volume":"20","author":"G\u00f3mez-Outes","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"11","key":"2021032516260235400_B364","first-page":"258","article-title":"Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism","volume":"10","author":"Cundiff","year":"2008","journal-title":"Medscape J Med"},{"issue":"13","key":"2021032516260235400_B365","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"issue":"9","key":"2021032516260235400_B366","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ajh.20691","article-title":"Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature","volume":"81","author":"Streiff","year":"2006","journal-title":"Am J Hematol"},{"issue":"4","key":"2021032516260235400_B367","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.thromres.2015.07.022","article-title":"Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis","volume":"136","author":"Sindet-Pedersen","year":"2015","journal-title":"Thromb Res"},{"issue":"8","key":"2021032516260235400_B368","first-page":"CD001367","article-title":"Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism","author":"Middeldorp","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2021032516260235400_B369","doi-asserted-by":"crossref","first-page":"e0143252","DOI":"10.1371\/journal.pone.0143252","article-title":"Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis","volume":"10","author":"Marik","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2021032516260235400_B370","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2796.2000.00631.x","article-title":"Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials","volume":"247","author":"Pinede","year":"2000","journal-title":"J Intern Med"},{"issue":"5","key":"2021032516260235400_B371","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.thromres.2015.02.032","article-title":"Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis","volume":"135","author":"Sobieraj","year":"2015","journal-title":"Thromb Res"},{"issue":"6","key":"2021032516260235400_B372","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.294.6.706","article-title":"Duration of anticoagulation following venous thromboembolism: a meta-analysis","volume":"294","author":"Ost","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"2021032516260235400_B373","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/jth.12501","article-title":"Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis","volume":"12","author":"Castellucci","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2021032516260235400_B374","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2016.01.005","article-title":"Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials","volume":"139","author":"Bova","year":"2016","journal-title":"Thromb Res"},{"issue":"8","key":"2021032516260235400_B375","doi-asserted-by":"crossref","first-page":"e0160064","DOI":"10.1371\/journal.pone.0160064","article-title":"Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"11","author":"Cohen","year":"2016","journal-title":"PLoS One"},{"key":"2021032516260235400_B376","doi-asserted-by":"crossref","first-page":"f5133","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"347","author":"Castellucci","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"2021032516260235400_B377","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40265-013-0082-7","article-title":"Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials","volume":"73","author":"Sardar","year":"2013","journal-title":"Drugs"},{"issue":"5","key":"2021032516260235400_B378","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","article-title":"Editor\u2019s Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials","volume":"48","author":"Kakkos","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"2021032516260235400_B379","first-page":"301","article-title":"Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis","volume":"33","author":"Alotaibi","year":"2014","journal-title":"Int Angiol"},{"key":"2021032516260235400_B380","doi-asserted-by":"crossref","first-page":"540386","DOI":"10.1155\/2010\/540386","article-title":"Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a meta-analysis","volume":"2010","author":"Holley","year":"2010","journal-title":"Thrombosis"},{"issue":"8","key":"2021032516260235400_B381","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"18","key":"2021032516260235400_B382","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"2021032516260235400_B383","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"2021032516260235400_B384","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1056\/NEJMoa054444","article-title":"D-dimer testing to determine the duration of anticoagulation therapy","volume":"355","author":"Palareti","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2021032516260235400_B385","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"2021032516260235400_B386","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-008-0626-1","article-title":"6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII","volume":"88","author":"Eischer","year":"2009","journal-title":"Ann Hematol"},{"issue":"1","key":"2021032516260235400_B387","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE Randomized Clinical Trial","volume":"314","author":"Couturaud","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"2021032516260235400_B388","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-139-1-200307010-00008","article-title":"Extended oral anticoagulant therapy after a first episode of pulmonary embolism","volume":"139","author":"Agnelli","year":"2003","journal-title":"Ann Intern Med"},{"issue":"26","key":"2021032516260235400_B389","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2021032516260235400_B390","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2021032516260235400_B391","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1024\/0301-1526.38.3.238","article-title":"The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment","volume":"38","author":"V\u00edtovec","year":"2009","journal-title":"Vasa"},{"issue":"3","key":"2021032516260235400_B392","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis","volume":"345","author":"Agnelli","year":"2001","journal-title":"N Engl J Med"},{"issue":"21","key":"2021032516260235400_B393","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"key":"2021032516260235400_B394","doi-asserted-by":"crossref","first-page":"bmjspcare-2019-001804","DOI":"10.1136\/bmjspcare-2019-001804","article-title":"Management of venous thromboembolism in far-advanced cancer: current practice","author":"Noble","year":"2019","journal-title":"BMJ Support Palliat Care"},{"issue":"7","key":"2021032516260235400_B395","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2021032516260235400_B396","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study","volume":"17","author":"Di Nisio","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2021032516260235400_B397","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2021032516260235400_B398","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021032516260235400_B399","unstructured":"National Comprehensive Cancer Network. NCCN guidelines. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#supportive. Accessed 13 January 2021."},{"key":"2021032516260235400_B400","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2021032516260235400_B401","unstructured":"Agency for Healthcare Research and Quality. Preventing hospital-associated venous thromboembolism: a guide for effective quality improvement. https:\/\/www.ahrq.gov\/sites\/default\/files\/publications\/files\/vteguide.pdf. Accessed 11 January 2021."},{"key":"2021032516260235400_B402"},{"key":"2021032516260235400_B403"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2021004734","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/4\/927\/1803860\/advancesadv2020003442c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/4\/927\/1803860\/advancesadv2020003442c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T02:37:20Z","timestamp":1698633440000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/4\/927\/475194\/American-Society-of-Hematology-2021-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":403,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003442","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}